Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
euglena Co., Ltd. ( (JP:2931) ) has issued an update.
Euglena Co., Ltd. reported a significant financial performance improvement in FY2025 Q1, with a 7% increase in sales and a 44% rise in adjusted EBITDA. The company is advancing its biofuel and healthcare businesses by securing subsidies for feedstock procurement and expanding its product applications. The consolidation of Saticine Medical Group contributed to increased net sales, while profitability was enhanced through structural improvements and cost reductions.
More about euglena Co., Ltd.
Euglena Co., Ltd. operates in the biotechnology industry, focusing on the development and commercialization of biofuels and healthcare products. The company is listed on the Prime Market of the Tokyo Stock Exchange and is known for its innovative use of algae cultivation in creating sustainable solutions.
Average Trading Volume: 786,198
Technical Sentiment Signal: Sell
Current Market Cap: Yen62.88B
See more insights into 2931 stock on TipRanks’ Stock Analysis page.